Condition: Non Hodgkin Lymphoma (NHL) · Mantle Cell Lymphoma (MCL) · Chronic Lymphocytic Leukemia (CLL) · Sponsor: Medical College of Wisconsin
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
This description comes directly from the study's public registry record.
Medical College of Wisconsin Cancer Center Clinical Trials Office · 866-680-0505 · cccto@mcw.edu
Always discuss trial participation with your own doctor first.
| Medical College of Wisconsin and Froedtert Hospital | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04186520